Shanghai Fosun Pharmaceutical Group Co Ltd

Fosun Pharmaceutical’s new approvals for LBP‑ShC4 and HLX07‑Suluimab mark a leap forward in biologic cancer and hair‑loss treatments, expanding global impact.

Shanghai Fosun Pharmaceutical’s stock shows stability amid a sharp 226.6% rise in short interest—investors should weigh its solid valuation against growing skepticism.

Shanghai Fosun Pharmaceutical Group’s latest drug registration approval shows its expanding global reach, balanced valuation, and steady growth in a volatile market.

Shanghai Fosun Pharmaceutical’s recent equity investment and strong 2025‑26 performance reveal a resilient, growth‑oriented pharma leader poised to innovate and capture market share.

Fosun Pharma’s new private fund and high‑risk Alzheimer’s drug deal reveal bold bets that could boost or hurt investor value—will the Chengdu‑focused vehicle deliver alpha?

Fosun Pharma’s $200 M bid for Green Valley’s Alzheimer’s drug sparks stock dip amid regulatory scrutiny, highlighting high‑risk expansion into neuro‑therapeutics.

Shanghai Fosun Pharmaceutical’s latest insurance catalogue entries and exclusive partnership with Pfizer unlock new revenue streams for its GLP‑1R platform, boosting market prospects.

Fosun Pharma launches Phase I trials for FXS887, a novel ATR‑kinase inhibitor, positioning it as a leading force in China’s growing biopharma oncology sector.

Shanghai Fosun Pharmaceutical’s latest market snapshot shows a resilient P/E of 16.75 and diversified product mix poised to capitalize on China’s expanding healthcare and drug‑pricing reforms.

Shanghai Fosun Pharmaceutical Group Co Ltd, a diversified Chinese healthcare company, faces challenges in navigating uncertain markets, regulatory pressures, and shifting government priorities, but has opportunities to drive growth through innovatio…